Chameleon Biosciences, Inc.

Funding reportedLast round: Seed

ResearchBerkeley, United States

About Chameleon Biosciences, Inc.

is a biotechnology company based in Berkeley, California, specializing in gene therapy. Founded in 2017, the company focuses on developing next-generation adeno-associated virus (AAV) therapies that aim to reduce immune responses and enable repeat dosing. The company's main platform, EVADERTM, is designed to enhance AAV vector delivery by minimizing antibody production and masking foreign proteins. This technology seeks to lower the immune response associated with gene therapies, potentially expanding access for patients with various genetic disorders, as well as applications in oncology, ophthalmology, and pediatric disorders. Chameleon Biosciences operates in a B2B context, targeting biopharmaceutical partners and researchers in the life sciences sector.

What company datasets say Chameleon Biosciences, Inc. raised

Funding, as reported

Reported in all$14Min dollars

Rounds5

Last roundSeed

Last round dateNov 2022

Investors listed9

Founders and team

From the SEC filings it signed: 1 on the team.

Genine A. WinslowExecutive Officer, Directori

On the board, as filediRan A. GengWinnie A. Wan

On 3 portfolio pages

Investors who name them

Each firm lists Chameleon Biosciences, Inc. on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

The company, in detail

What they build

Known for

biotechnology research

Sector: Research
Region: California
Full record: Every detail in the company directory

Research in United States

Startups like it

Is this your company?

Add your raise, your deck and your story, and put Chameleon Biosciences, Inc. in front of investors. Or tell us what we have wrong.

List your startup Send a correction